TheProfitWatch

IKT - Inhibikase Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
1.52 -0.01 (-0.33%) 0.0 (0.0%) -0.01 (-0.33%) -0.06 (-3.81%) 0.07 (4.61%) -0.06 (-3.5%) 0.1 (6.67%) 0.09 (6.0%)

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.11
Diluted EPS:
-0.11
Basic P/E:
-13.7727
Diluted P/E:
-13.7727
RSI(14) 1m:
24.75
VWAP:
1.52
RVol:

Events

Period Kind Movement Occurred At

Related News